Social networks
1,542 3,848 16,799Activities
Technologies
Entity types
Location
60 Rue de Wattignies, 75012 Paris, France
Paris
France
Employees
Scale: 51-200
Estimated: 141
SIREN
447521600Engaged corporates
15Added in Motherbase
6 years, 2 months agoLeading, late clinical-stage nanomedicine company pioneering new approaches to significantly change patient outcomes.
Incorporated in 2003, Nanobiotix is a leading, late clinical-stage nanomedicine company pioneering new approaches to significantly change patient outcomes by bringing nanophysics to the heart of the cell.
The Nanobiotix philosophy is one rooted in designing pioneer physical based approaches to bring highly effective and generalized solutions to address high unmet medical needs and challenges.
Nanobiotix’s novel first-in-class, proprietary lead technology, NBTXR3, aims to expand radiotherapy benefits for millions of cancer patients. Furthermore, Nanobiotix’s Immuno-Oncology program has the potential to bring a new dimension to cancer immunotherapies.
Nanobiotix is listed on the regulated market of Euronext in Paris (Euronext: NANO / ISIN: FR0011341205; Bloomberg: NANO: FP) and on the Nasdaq Global Select Market (Nasdaq: NBTX). The Company’s headquarters are based in Paris, France, with a U.S. affiliate in Cambridge, MA, and European affiliates in Spain and Germany. More: www.nanobiotix.com
Nanomedicine, Pharma, Biotechnology, Oncology, Radiotherapy, Immuno-oncology, Nanoparticles, and Nanotechnology
Leading, late clinical-stage nanomedicine company pioneering new approaches to significantly change patient outcomes.
Incorporated in 2003, Nanobiotix is a leading, late clinical-stage nanomedicine company pioneering new approaches to significantly change patient outcomes by bringing nanophysics to the heart of the cell.
The Nanobiotix philosophy is one rooted in designing pioneer physical based approaches to bring highly effective and generalized solutions to address high unmet medical needs and challenges.
Nanobiotix’s novel first-in-class, proprietary lead technology, NBTXR3, aims to expand radiotherapy benefits for millions of cancer patients. Furthermore, Nanobiotix’s Immuno-Oncology program has the potential to bring a new dimension to cancer immunotherapies.
Nanobiotix is listed on the regulated market of Euronext in Paris (Euronext: NANO / ISIN: FR0011341205; Bloomberg: NANO: FP) and on the Nasdaq Global Select Market (Nasdaq: NBTX). The Company’s headquarters are based in Paris, France, with a U.S. affiliate in Cambridge, MA, and European affiliates in Spain and Germany. More: www.nanobiotix.com
Nanobiotix is a biotechnology company pioneering the discovery, development, manufacture, and commercialization of physics-based nanomedicines
Corporate | Type | Tweets | Articles | |
---|---|---|---|---|
CCI Paris IdF Chamber of commerce, Government Administration | CCI Paris IdF Chamber of commerce, Government Administration | Other 18 Jul 2024 | | |
Karista Startup accelerator & VC, Venture Capital and Private Equity Principals | Karista Startup accelerator & VC, Venture Capital and Private Equity Principals | Other 21 Dec 2023 | | |
Le Figaro Media, Newspaper Publishing | Le Figaro Media, Newspaper Publishing | Other 12 Jul 2023 | | |
BFM Business Media, Broadcast Media Production and Distribution | BFM Business Media, Broadcast Media Production and Distribution | Other 17 Aug 2020 | | |
Institut Curie Health, Hospitals and Health Care | Institut Curie Health, Hospitals and Health Care | Not capitalistic Partnership Event 29 Mar 2022 27 Mar 2023 | | |
Euronext Finance, Financial Services | Euronext Finance, Financial Services | Not capitalistic Not partnership Event 19 Sep 2019 | | |
Nasdaq Finance, Financial Services | Nasdaq Finance, Financial Services | Not capitalistic Partnership Not event 9 Apr 2021 | | |
La French Tech Media, Government Administration | La French Tech Media, Government Administration | Not capitalistic Not partnership Event 12 Dec 2020 | | |
Sanofi Pharmaceutical, Pharmaceutical Manufacturing | Sanofi Pharmaceutical, Pharmaceutical Manufacturing | Capitalistic Partnership Not event 26 Jan 2021 | | |
Johnson & Johnson Pharmaceutical, Hospitals and Health Care | Johnson & Johnson Pharmaceutical, Hospitals and Health Care | Other 7 Sep 2020 28 Jul 2023 | | |